B. Brooks

发表

Supported treadmill ambulation for amyotrophic lateral sclerosis: a pilot study.

M. Sanjak, E. Bravver, W. Bockenek, 2010, Archives of physical medicine and rehabilitation.

Power wheelchair prescription, utilization, satisfaction, and cost for patients with amyotrophic lateral sclerosis: preliminary data for evidence-based guidelines.

M. Sanjak, E. Bravver, B. Brooks, 2010, Archives of physical medicine and rehabilitation.

Power Wheelchair Use in Persons With Amyotrophic Lateral Sclerosis: Changes Over Time

E. Bravver, B. Brooks, Amber Ward, 2015, Assistive technology : the official journal of RESNA.

El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis

M. Swash, T. Munsat, Robert G. Miller, 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Quality improvement in neurology: Amyotrophic Lateral Sclerosis Quality Measures

Adam B. Cohen, Robert G. Miller, R. Dubinsky, 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Natural history of ALS

B. Brooks, 1996, Neurology.

A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson’s disease

Sterling C. Johnson, J. Abbs, J. Holden, 2011, Brain Imaging and Behavior.

Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype.

D. Bhattacharyya, B. Brooks, L. Callahan, 1996, AIDS research and human retroviruses.

Hypoglossal, trigeminal, and facial motoneuron involvement in amyotrophic lateral sclerosis

J. Abbs, B. Brooks, M. Caligiuri, 1988, Neurology.

Multiple orofacial indices in amyotrophic lateral sclerosis.

B. Brooks, R. DePaul, B R Brooks, 1993, Journal of speech and hearing research.

Impairment of speech intelligibility in men with amyotrophic lateral sclerosis.

Raymond D. Kent, R D Kent, G Weismer, 1990, The Journal of speech and hearing disorders.

Speech deterioration in amyotrophic lateral sclerosis: a case study.

Raymond D. Kent, R D Kent, G Weismer, 1991, Journal of speech and hearing research.

Quantitative description of the dysarthria in women with amyotrophic lateral sclerosis.

Raymond D. Kent, R D Kent, G Weismer, 1992, Journal of speech and hearing research.

Controversies and priorities in amyotrophic lateral sclerosis

M. Swash, A. Chiò, O. Hardiman, 2013, The Lancet Neurology.

El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis

B. Brooks, Benjamin Rix Brooks, 1994, Journal of the Neurological Sciences.

In Vitro Effects of Cholesterol β-d-Glucoside, Cholesterol and Cycad Phytosterol Glucosides on Respiration and Reactive Oxygen Species Generation in Brain Mitochondria

B. Brooks, A. Panov, C. Shaw, 2010, The Journal of Membrane Biology.

Metabolic and functional differences between brain and spinal cord mitochondria underlie different predisposition to pathology.

H. Bonkovsky, N. Zinchenko, B. Brooks, 2011, American journal of physiology. Regulatory, integrative and comparative physiology.

The Neuromediator Glutamate, through Specific Substrate Interactions, Enhances Mitochondrial ATP Production and Reactive Oxygen Species Generation in Nonsynaptic Brain Mitochondria*

H. Bonkovsky, B. Brooks, A. Panov, 2009, Journal of Biological Chemistry.

American Academy of Neurology evidence-based review): Report of the Quality Standards Subcommittee of the Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an

R. Sufit, M. Bromberg, T. Munsat, 2006 .

Care of the Patient with ALS Page 3

R. Sufit, M. Bromberg, T. Munsat, 2003 .

Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidence‐based review)

R. Sufit, M. Bromberg, H. Mitsumoto, 1999, Muscle & nerve.

The ALS Patient Care Database

T. Munsat, H. Mitsumoto, W. Bradley, 2000, Neurology.

Risk factors in the early diagnosis of ALS: North American epidemiological studies

B. Brooks, 2000 .

Consensus guidelines for the design and implementation of clinical trials in ALS

M. Swash, T. Munsat, Robert G. Miller, 1999, Journal of the Neurological Sciences.

Managing amyotrophic lateral sclerosis: Slowing disease progression and improving patient quality of life

B. Brooks, 2009, Annals of neurology.

Pathophysiology of Cerebrospinal Fluid Immunoglobulins

B. Brooks, J. Trotter, 1980 .

Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia

W. Engel, K. Ahmeti, Wenjie Chen, 2010, Neurology.

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

G. Barger, S. Reingold, C. Bever, 2000, Multiple sclerosis.

Synthesis of Virus-Specific High-Mobility DNA after Temperature Upshift of SC-1 Cells Chronically Infected with Moloney Murine Leukemia Virus Mutant ts1

B. Brooks, P. Szurek, 2000, Journal of Virology.

Disease activity and emotional state in multiple sclerosis

P. Rabins, B. Brooks, N. Dalos, 1983, Annals of neurology.

Cerebrospinal fluid acid‐base and lactate changes after seizures in unanesthetized man

R. D. Adams, B. Brooks, 1975, Neurology.

Quality improvement in neurology: Amyotrophic lateral sclerosis quality measures

Adam B. Cohen, Robert G. Miller, R. Dubinsky, 2013, Neurology.

Neurotoxic injury pathways in differentiated mouse motor neuron-neuroblastoma hybrid (NSC-34D) cells in vitro--limited effect of riluzole on thapsigargin, but not staurosporine, hydrogen peroxide and homocysteine neurotoxicity.

B. Brooks, R. Hemendinger, Nick Radio, 2012, Toxicology and applied pharmacology.

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine

R. Thisted, R. Olney, W. Bradley, 2004, Neurology.

Randomized parallel placebo controlled pilot study of intravenous trh administration in amyotrophic lateral sclerosis patients increased strength and functional ability

J. Abbs, R. Sufit, R. Serlin, 1985 .

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].

R. Schiffer, L. Weiner, J. Wolinsky, 2001, Neurology.

Cerebrospinal fluid norepinephrine and free γ-aminobutyric acid in amyotrophic lateral sclerosis

W. Engel, B. Brooks, C. Lake, 1980, Brain Research Bulletin.

Norepinephrine and gamma‐aminobutyric acid in amyotrophic lateral sclerosis

B. Brooks, M. Ziegler, S. Enna, 1980, Neurology.

Cerebrospinal Fluid γ-Aminobutyric Acid Correlation with Cerebrospinal Fluid and Blood Constituents and Alterations in Neurological Disorders

B. Brooks, M. Ziegler, S. Enna, 1980 .

Relationship between cerebrospinal fluid norepinephrine and blood pressure in neurologic patients.

B. Brooks, M. Ziegler, C. Lake, 1980, Clinical and experimental hypertension.

Relationship between norepinephrine in blood and cerebrospinal fluid in the presence of a blood cerebrospinal fluid barrier for norepinephrine

B. Brooks, M. Ebert, C. Lake, 1977, Journal of neurochemistry.

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS)

M. Benatar, M. Cudkowicz, R. Bowser, 2020, Neurology. Clinical practice.

CuZnSOD and MnSOD immunoreactivity in brain stem motor neurons from amyotropic lateral sclerosis patients

N. Taniguchi, B. Brooks, H. A. Hartmann, 1997, Acta Neuropathologica.

Clinical evaluation of ALS drugs

B. Brooks, 1997, Neurology.

Dropped head syndrome

B. Brooks, A. Waclawik, B. Lotz, 1997, Neurology.

A Summary of the Current Position of TRH in ALS Therapy a

B. Brooks, 1989, Annals of the New York Academy of Sciences.

Excitotoxicity hypothesis. Discussion

J. Rothstein, B. Brooks, D. Cleveland, 1996 .

ALS-Plus — Where does it begin, where does it end?

B. Brooks, 2014, Journal of the Neurological Sciences.

Physiologic and metabolic response to progressive and prolonged exercise in amyotrophic lateral sclerosis

R. Sufit, M. Sanjak, B. Brooks, 1987, Neurology.

Linkage analysis in familial amyotrophic lateral sclerosis

M. Pericak-Vance, W. Hung, N. Siddique, 1989, Neurology.

Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.

J. Shefner, B. Brooks, J. Jorgenson, 2018, The American journal of managed care.

Hypercaloric enteral nutrition in Amyotrophic Lateral Sclerosis: a randomized double-blind placebo-controlled trial

J. Lou, J. Glass, H. Mitsumoto, 2014 .

Title Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis : a randomised , double-blind , placebo-controlled phase 2 trial

J. Lou, J. Glass, M. Cudkowicz, 2014 .

Problems in shortening the time to confirmation of ALS diagnosis: lessons from the 1st Consensus Conference, Chicago, May 1998

B. Brooks, B. R. Brooks, 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Diagnostic dilemmas in amyotrophic lateral sclerosis

B. Brooks, 1999, Journal of the Neurological Sciences.

ALS standard of care consensus

R. Sufit, H. Mitsumoto, Robert G. Miller, 1997, Neurology.

A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

Gary L. Pattee, Stephen A. Goutman, O. Hardiman, 2020, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Functional magnetic resonance imaging (fMRI) clinical studies in ALS--paradigms, problems and promises.

K. Bushara, H. Henningsen, B. Brooks, 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Issues in clinical trial design II

M. Bromberg, B. Brooks, 1996, Neurology.

Natural history of amyotrophic lateral sclerosis. Quantification of symptoms, signs, strength, and function.

M. Sanjak, B. Brooks, D. Belden, 1995, Advances in neurology.

Design of clinical therapeutic trials in amyotrophic lateral sclerosis.

R. Sufit, J. Robbins, M. Sanjak, 1991, Advances in neurology.

The Role of Axonal Transport in Neurodegenerative Disease Spread: A Meta-Analysis of Experimental and Clinical Poliomyelitis Compares with Amyotrophic Lateral Sclerosis

B. Brooks, 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis

A. Pestronk, D. Schoenfeld, M. Cudkowicz, 2020, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Frontotemporal Hypometabolism in Amyotrophic Lateral Sclerosis‐Dementia Complex

J. Rosenbek, R. Nickles, B. Brooks, 1993 .

X-linked Dominant ALS

J. Haines, W. Hung, N. Siddique, 1998, Neurology.

Oligoclonal IgG bands in cerebrospinal fluid in various neurological diseases

B. Brooks, J. Sever, D. Madden, 1983, Annals of neurology.

Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis

E. Pioro, C. Jackson, B. Brooks, 2020, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Disease‐modifying drug therapies

M. Sanjak, B. Brooks, 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Cellular and Humoral Immune Responses in Human Cerebrospinal Fluid

R. Hirsch, B. Brooks, P. Coyle, 1983 .

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

J. W. Rose, Jeffrey A. Cohen, R. Schiffer, 1995, Neurology.

Alteration from T- to B-cell tropism reduces thymic atrophy and cytocidal effects in thymocytes but not neurovirulence induced by ts1, a mutant of Moloney murine leukemia virus TB.

P. K. Wong, B. Brooks, K. Saha, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Methyl Vitamin B12 but not methylfolate rescues a motor neuron-like cell line from homocysteine-mediated cell death.

B. Brooks, R. Hemendinger, E. J. Armstrong, 2011, Toxicology and applied pharmacology.

Effects of Various Disease States and Immunosuppressive Drugs

J. Cook, B. Brooks, 1980 .

Lymphocyte Subpopulations in Human Cerebrospinal Fluid

J. Cook, B. Brooks, Jay D. Cook, 1980 .

Elevations in cerebrospinal fluid norepinephrine during unilateral and bilateral cerebellar stimulation in man.

J. V. Van Buren, B. Brooks, M. Ziegler, 1977, Neurosurgery.

Spongiform polioencephalomyelopathy caused by a murine retrovirus. I. Pathogenesis of infection in newborn mice.

B. Brooks, R. Johnson, J. R. Swarz, 1980, Laboratory investigation; a journal of technical methods and pathology.

Modification of non-invasive ventilation for the advanced amyotrophic lateral sclerosis patient during the COVID-19 pandemic - do it now

B. Brooks, E. Young, B. Sah, 2020, Journal of the Neurological Sciences.

Progressive multifocal leukoencephalopathy.

B. Brooks, D. Walker, 1984, Neurologic clinics.

Failure to detect enterovirus in the spinal cord of ALS patients using a sensitive RT-PCR method

M. Pallansch, R. Roos, B. Brooks, 2004, Neurology.

Cerebrospinal Fluid Immunoglobulins

B. Brooks, J. Trotter, 1980 .

CEREBROSPINAL-FLUID LYMPHOCYTE POPULATIONS AND IMMUNE COMPLEXES IN ACTIVE MULTIPLE SCLEROSIS

J. Wolinsky, R. Hirsch, B. Brooks, 1980, The Lancet.

Nonimmunoglobulin Proteins in Human Cerebrospinal Fluid

B. Brooks, 1989 .

Debating the possibility of earlier diagnosis of patients with amyotrophic lateral sclerosis

B. Brooks, 2000 .

Defining optimal management in ALS: from first symptoms to announcement.

B. Brooks, 1999, Neurology.

A diagnostic index of active demyelination: Myelin basic protein in cerebrospinal fluid

R. Herndon, G. McKhann, B. Brooks, 1980, Annals of neurology.

Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool

Albert A. Taylor, E. Pioro, D. Ennist, 2021, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Measles virus vaccination of measles seropositive individuals suppresses lymphocyte proliferation and chemotactic factor production.

J. Hess, R. Hirsch, D. Griffin, 1981, Clinical immunology and immunopathology.

Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review)

R. Sufit, M. Bromberg, T. Munsat, 1999, Neurology.

Home ventilation for amyotrophic lateral sclerosis patients

C. Stocking, M. Siegler, R. Roos, 1993, Neurology.

Cerebrospinal fluid myelin basic protein in hydrocephalus.

S. Barrer, B. Brooks, L. Sutton, 1983, Journal of neurosurgery.

Practice Parameter: The Care of the Patient with Amyotrophic Lateral Sclerosis (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

T L Munsat, M B Bromberg, R. Sufit, 1999, Neurology.

Validation of robust tools to measure sialorrhea in amyotrophic lateral sclerosis: A study in a large French cohort

S. Tezenas du Montcel, F. Salachas, N. le Forestier, 2013, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Neuropeptide degradation by large vessel and microvessel-derived endothelial cells in vitro: cell surface catabolism of thyrotropin releasing hormone (TRH)

B. Brooks, J. Turner, J. Rozental, 1989, Brain Research.

Thyrotropin-releasing hormone (TRH) degradation in NIH:N mouse cerebral cortex and spinal cord

B. Brooks, J. Turner, T. Schwartz, 1986, Neuroscience Letters.

Cerebrospinal fluid GABA variations with seizure type and cerebellar stimulation in man

R. Post, J. Ballenger, B. Brooks, 1980, Brain Research Bulletin.

Neurotransmitter, Metabolite, and Cyclic Nucleotide Alterations in Cerebrospinal Fluid of Seizure Patients

B. Brooks, J. Wood, 1980 .

Vestibular deficits leading to disequilibrium and falls in ambulatory amyotrophic lateral sclerosis.

M. Sanjak, E. Bravver, W. Bockenek, 2014, Archives of physical medicine and rehabilitation.

Amyotrophic lateral sclerosis. A case-control study following detection of a cluster in a small Wisconsin community.

J. Taylor, B. Brooks, D. Sienko, 1990, Archives of neurology.

Cellular immunity and hepatitis-associated-antigen liver disease.

B. Brooks, Benjamin Rix Brooks, 1972, Lancet.

Spinal cord metabolic changes in murine retrovirus-induced motor neuron disease

B. Brooks, G. Feussner, W.David Lust, 1983, Brain Research Bulletin.

Myopathic Dropped Head Syndrome: An Expanding Clinicopathological Spectrum

B. Brooks, A. Waclawik, B. Lotz, 2007, American journal of physical medicine & rehabilitation.

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Jeffrey A. Cohen, R. Schiffer, L. Weiner, 1995, Neurology.

A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis

D. Schoenfeld, M. Cudkowicz, L. Clawson, 2018, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Extracellular Cyclic Nucleotide Metabolism in the Human Central Nervous System

W. Engel, B. Brooks, M. Ebert, 1980 .

Mutations in UBQLN2 cause dominant X-linked juvenile and adult onset ALS and ALS/dementia

J. Haines, M. Pericak-Vance, E. Mugnaini, 2011, Nature.

Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration.

B. Brooks, P. Bettica, S. Cazzaniga, 2019, Clinical therapeutics.

ts1-Induced spongiform encephalomyelopathy: physical forms of high-mobility DNA in spinal cord tissues of paralyzed mice are products of premature termination of reverse transcription

B. Brooks, P. Szurek, 1996, Journal of virology.

Development of physical forms of unintegrated retroviral DNA in mouse spinal cord tissue during ts1-induced spongiform encephalomyelopathy: elevated levels of a novel single-stranded form in paralyzed mice

B. Brooks, P. Szurek, Benjamin Rix Brooks, 1995, Journal of virology.

Clinical epidemiology of amyotrophic lateral sclerosis.

B. Brooks, B R Brooks, 1996, Neurologic clinics.

Adult-onset acid maltase deficiency. Morphologic and biochemical abnormalities reproduced in in cultured muscle.

S. Dimauro, W. Engel, B. Brooks, 1976, The New England journal of medicine.

Myelin Basic Protein in Cerebrospinal Fluid Index of Active Demyelination

R. Herndon, G. McKhann, B. Brooks, 1980 .

Frontiers in Clinical Neuroscience

B. Brooks, J. Wood, 2004, Advances in Experimental Medicine and Biology.

Cerebrospinal fluid acid‐base and lactate changes after seizures in unanesthetized man

R. D. Adams, B. Brooks, 1975, Neurology.

Microarray analysis of peripheral blood lymphocytes from ALS patients and the SAFE detection of the KEGG ALS pathway

Fred A Wright, F. Wright, B. Brooks, 2011, BMC Medical Genomics.

CSF viral antibodies. Evaluation in amyotrophic lateral sclerosis and late-onset postpoliomyelitis progressive muscular atrophy.

W. Engel, B. Brooks, J. Sever, 1979, Archives of neurology.

The LO-BaFL method and ALS microarray expression analysis

Kevin J. Thompson, B. Brooks, Jean-Luc C Mougeot, 2012, BMC Bioinformatics.

Deoxyglucose uptake by mouse astrocytes: Effects of temperature and retrovirus infection

B. Brooks, J. Vann, Benjamin, 1995, Neurochemical Research.

Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?

H. Mitsumoto, V. Silani, B. Brooks, 2014, The Lancet Neurology.

Computerized axial tomography

J. Schnur, F. Hochberg, B. Brooks, 1975, Neurology.

Slow viral infections.

B. Brooks, B. Jubelt, R. Johnson, 1979, Annual Review of Neuroscience.

Emotional disturbance in multiple sclerosis patients: validity of the General Health Questionnaire (GHQ)

P. Rabins, B. Brooks, 1981, Psychological Medicine.

Seizure-Induced Metabolic Alterations in Human Cerebrospinal Fluid

B. Brooks, 1980 .

Murine neurotropic retrovirus spongiform polioencephalomyelopathy: acceleration of disease by virus inoculum concentration

O. Narayan, B. Brooks, R. Johnson, 1979, Infection and immunity.

Correlation of specific virus-astrocyte interactions and cytopathic effects induced by ts1, a neurovirulent mutant of Moloney murine leukemia virus

B. Brooks, K. Saha, Y. C. Lin, 1993, Journal of virology.

Murine leukemia virus induced central nervous system diseases.

B. Brooks, R. Madden, K. Saha, 1992, Leukemia.

Whole-genome association studies of sporadic amyotrophic lateral sclerosis: are retroelements involved?

B. Brooks, Jean-Luc C Mougeot, Stephanie Richardson-Milazi, 2009, Trends in molecular medicine.

17 – Progressive Multifocal Leukoencephalopathy

B. Brooks, 2007 .

Six-Minute Walk Test as a Measure of Walking Capacity in Ambulatory Individuals With Amyotrophic Lateral Sclerosis.

Nigel Rozario, M. Sanjak, E. Bravver, 2017, Archives of physical medicine and rehabilitation.

Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]

B. Brooks, T. Heiman-Patterson, M. Wiedau-Pazos, 2022, PloS one.

Rapid separation of tritiated thyrotropin-releasing hormone and its catabolic products from mouse and human central nervous system tissues by high-performance liquid chromatography with radioactive flow detection.

B. Brooks, J. Turner, T. Schwartz, 1989, Journal of chromatography.

Defining and Diagnosing Involuntary Emotional Expression Disorder

Daniel Weintraub, Erik P Pioro, R. Schiffer, 2006, CNS Spectrums.

PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions

B. Brooks, D. Kantor, Randall Kaye, 2013, PloS one.

Outcomes research in amyotrophic lateral sclerosis: Lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database

H. Mitsumoto, Robert G. Miller, W. Bradley, 2009, Annals of neurology.

Acute posterior multifocal placoid pigment epitheliopathy associated with cerebral vasculitis.

G. Bresnick, C. Strother, B. Brooks, 1988, Journal of clinical neuro-ophthalmology.

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

J S Wolinsky, R. Schiffer, L. Weiner, 1998, Neurology.

Demonstration of thyrotropin-releasing hormone immunoreactivity in neurons of the mouse spinal dorsal horn

B. Brooks, J. Coffield, V. Miletić, 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Structural brain correlates of emotional disorder in multiple sclerosis.

G. Pearlson, P. Rabins, M. Folstein, 1986, Brain : a journal of neurology.

Patient Teaching Manuals Improve Retention of Treatment Information— A Controlled Clinical Trial In Multiple Sclerosis

B. Brooks, F. Young, 1986, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials

A. Chiò, L. H. van den Berg, M. Benatar, 2019, Neurology.

Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect

Jeffrey Cummings, Erik P Pioro, R. Schiffer, 2010, Annals of neurology.

Cerebrospinal Fluid Noradrenergic and Behavioral Alterations Associated with Stimulation and Atrophy of the Caudate Nucleus

I. Shoulson, B. Brooks, M. Ziegler, 1980 .

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

V. Meininger, W. Robberecht, A. Eisen, 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Subcortical reorganization in amyotrophic lateral sclerosis

S. Knecht, A. Jansen, C. Konrad, 2006, Experimental Brain Research.

Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis

Y. Liu, B. Brooks, J. Berry, 2022, EClinicalMedicine.

Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study

Carsten Konrad, Benjamin Brooks, Michael Deppe, 2002, Experimental Brain Research.

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis

Kaila L. Stipancic, Stephen A. Goutman, Jordan R. Green, 2019, Muscle & nerve.

A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS

L. H. van den Berg, M. Cudkowicz, H. Mitsumoto, 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Treatment of pseudobulbar affect in ALS

B. Brooks, Richard Smith, 2005, The Lancet Neurology.

Functional scales: Summary

B. Brooks, 2002, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Versailles minimal dataset for diagnosis of ALS: a distillate of the 2nd Consensus Conference on accelerating the diagnosis of ALS. Versailles 2nd Consensus Conference participants.

B. Brooks, 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis

V. Meininger, F. Salachas, M. Sanjak, 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

Effect of Bovine Serum Albumin on Mitochondrial Respiration in the Brain and Liver of Mice and Rats

H. Bonkovsky, B. Brooks, A. Panov, 2010, Bulletin of Experimental Biology and Medicine.

Risk factors in the early diagnosis of ALS: North American epidemiological studies. ALS CARE Study Group.

B. Brooks, 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Spinal seizures following intravenous contrast in a patient with a cord AVM

G. Uhl, B. Brooks, Carlos R. Marchtinez, 1981 .

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

L. Weiner, J. Wolinsky, J. Wolinsky, 2003, Multiple sclerosis.

Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies.

R. Sufit, B. Brooks, D. Beaulieu, 1987, Neurologic clinics.

Myelin Basic Protein in Cerebrospinal Fluid

R. Herndon, G. McKhann, B. Brooks, 1980 .

Cerebrospinal fluid GABA seizure patients evoked by surface stimulation reductions in cerebellar

B. Brooks, V. Buren, Glaeser, 2022 .

The Oral Secretion Scale and Prognostic Factors for Survival in Subjects With Amyotrophic Lateral Sclerosis

R. Chatburn, B. Brooks, P. Cazzolli, 2020, Respiratory Care.